NFATC2
NFATC2 (Nuclear factor of activated T-cells, cytoplasmic 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma, Breast cancer, Skin cancer and 3 more.
Overview
Plays a role in the inducible expression of cytokine genes in T-cells, especially in the induction of the IL-2, IL-3, IL-4, TNF or GM-CSF. Promotes invasive migration through the activation of GPC6 expression and WNT5A signalling pathway. Is involved in the negative regulation of chondrogenesis.
Open Targets scores its association with cancer at 0.64 (direct and indirect evidence; datatypes literature 0.97, animal model 0.52, genetic association 0.00, somatic mutation 0.83). IntOGen calls it a driver in 2 cohorts (1 activating, 1 loss-of-function), covering Pancreatic Adenocarcinoma, Rectal Adenocarcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · NFATC2 (Nuclear factor of activated T-cells, cytoplasmic 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma, Breast cancer, Skin cancer and 3 more.
- 1 · What it is
NFATC2 (Nuclear factor of activated T-cells, cytoplasmic 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma, Breast cancer, Skin cancer and 3 more.
- 2 · What goes wrong in cancer
Plays a role in the inducible expression of cytokine genes in T-cells, especially in the induction of the IL-2, IL-3, IL-4, TNF or GM-CSF. Promotes invasive migration through the activation of GPC6 expression and WNT5A signalling pathway.
- 3 · How drugs use it
No product in this corpus aims at NFATC2 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:7776 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q13469 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000101096 (association with cancer (MONDO_0004992) 0.64; per-cancer scores at or above 0.5: colorectal cancer 0.52, gastric cancer 0.52, skin cancer 0.54, breast cancer 0.56 (GraphQL API, CC0)); IntOGen NFATC2 (driver in 2 cohorts (Act 1, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Plays a role in the inducible expression of cytokine genes in T-cells, especially in the induction of the IL-2, IL-3, IL-4, TNF or GM-CSF. Promotes invasive migration through the activation of GPC6 expression and WNT5A signalling pathway. Is involved in the negative regulation of chondrogenesis. Recruited by AKAP5 to ORAI1 pore-forming subunit of CRAC channels in Ca(2+) signalling microdomains where store-operated Ca(2+) influx is coupled to calmodulin and calcineurin signalling and activation of NFAT-dependent transcriptional responses. Location: Cytoplasm; Nucleus (UniProt). Locus 20q13.2 (HGNC).
- Pancreatic ductal adenocarcinoma: IntOGen driver in 1 cohort (PAAD)
- Breast cancer: Open Targets association 0.56 with breast cancer (MONDO_0007254)
- Skin cancer: Open Targets association 0.54 with skin cancer (MONDO_0002898)
- Gastric & gastro-oesophageal junction cancer: Open Targets association 0.52 with gastric cancer (MONDO_0001056)
- Colorectal cancer: Open Targets association 0.52 with colorectal cancer (MONDO_0005575)
- Rectal cancer: IntOGen driver in 1 cohort (READ)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"NFATC2" OR ABSTRACT:"NFATC2" OR TITLE:"nuclear factor of activated T cells 2" OR ABSTRACT:"nuclear factor of activated T cells 2" OR TITLE:"Nuclear factor of activated T-cells, cytoplasmic 2" OR ABSTRACT:"Nuclear factor of activated T-cells, cytoplasmic 2" OR TITLE:"NF-ATP" OR ABSTRACT:"NF-ATP" OR TITLE:"NFATp" OR ABSTRACT:"NFATp" OR TITLE:"NFAT1" OR ABSTRACT:"NFAT1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NFATC2, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetTCF7L2
Shares Rectal cancer, Skin cancer (all types), Breast cancer (all types), IntOGen.
- TargetAMER1
Shares Rectal cancer, Skin cancer (all types), IntOGen, Open Targets Platform.
- TargetMSH2
Shares Rectal cancer, Skin cancer (all types), Breast cancer (all types), Gastric & gastro-oesophageal junction cancer.
- TargetSOCS1
Shares Rectal cancer, IntOGen, Open Targets Platform.
- TrialTo Evaluate Dose and Safety of NanoEcho Particle-1 Using NanoEcho Imaging Device Examinations of Rectal Lymph Nodes in Healthy Volunteers and Rectal Cancer Patients.
Shares Rectal cancer, Colorectal cancer.
- TrialA Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer
Shares Rectal cancer, Colorectal cancer.
- TrialA Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum
Shares Rectal cancer, Colorectal cancer.
- TrialA Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China
Shares Rectal cancer, Colorectal cancer.